Vivoryon Therapeutics NV (VVY) - Net Assets
Based on the latest financial reports, Vivoryon Therapeutics NV (VVY) has net assets worth €4.73 Million EUR (≈ $5.53 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€7.52 Million ≈ $8.79 Million USD) and total liabilities (€2.79 Million ≈ $3.26 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Vivoryon Therapeutics NV asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €4.73 Million |
| % of Total Assets | 62.88% |
| Annual Growth Rate | -6.15% |
| 5-Year Change | -71.45% |
| 10-Year Change | 28765.41% |
| Growth Volatility | 893310.31 |
Vivoryon Therapeutics NV - Net Assets Trend (2010–2025)
This chart illustrates how Vivoryon Therapeutics NV's net assets have evolved over time, based on quarterly financial data. Also explore VVY total asset value for the complete picture of this company's asset base.
Annual Net Assets for Vivoryon Therapeutics NV (2010–2025)
The table below shows the annual net assets of Vivoryon Therapeutics NV from 2010 to 2025. For live valuation and market cap data, see VVY stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €4.73 Million ≈ $5.53 Million |
-40.01% |
| 2024-12-31 | €7.88 Million ≈ $9.21 Million |
-70.02% |
| 2023-12-31 | €26.28 Million ≈ $30.73 Million |
-0.85% |
| 2022-12-31 | €26.51 Million ≈ $30.99 Million |
+60.09% |
| 2021-12-31 | €16.56 Million ≈ $19.36 Million |
-36.86% |
| 2020-12-31 | €26.22 Million ≈ $30.66 Million |
-38.54% |
| 2019-12-31 | €42.66 Million ≈ $49.88 Million |
+3468599.19% |
| 2018-12-31 | €1.23K ≈ $1.44K |
-86.22% |
| 2017-12-31 | €8.92K ≈ $10.43K |
-45.51% |
| 2016-12-31 | €16.38K ≈ $19.15K |
+1.51% |
| 2015-12-31 | €16.13K ≈ $18.86K |
+1.01% |
| 2014-12-31 | €15.97K ≈ $18.67K |
+100.38% |
| 2013-12-31 | €-4.22 Million ≈ $-4.94 Million |
-178.73% |
| 2012-12-31 | €5.37 Million ≈ $6.27 Million |
-64.10% |
| 2011-12-31 | €14.95 Million ≈ $17.47 Million |
+22.11% |
| 2010-12-31 | €12.24 Million ≈ $14.31 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Vivoryon Therapeutics NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14143100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €296.00K | 6.26% |
| Other Comprehensive Income | €16.43 Million | 347.64% |
| Other Components | €166.22 Million | 3516.35% |
| Total Equity | €4.73 Million | 100.00% |
Vivoryon Therapeutics NV Competitors by Market Cap
The table below lists competitors of Vivoryon Therapeutics NV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Barfresh Food Group Inc
NASDAQ:BRFH
|
$37.94 Million |
|
Domiki Kritis S.A.
AT:DOMIK
|
$37.95 Million |
|
Puloon Technology Inc
KQ:094940
|
$37.98 Million |
|
Mishorim Real Estate Investments
TA:MSHR
|
$37.98 Million |
|
Aurumin Ltd
AU:AUN
|
$37.88 Million |
|
Saeron Auto
KO:075180
|
$37.86 Million |
|
AViTA Corporation
TWO:4735
|
$37.85 Million |
|
TechPrecision Corporation Common stock
NASDAQ:TPCS
|
$37.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vivoryon Therapeutics NV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,880,000 to 4,727,000, a change of -3,153,000 (-40.0%).
- Net loss of 8,853,000 reduced equity.
- New share issuances of 5,072,000 increased equity.
- Other comprehensive income increased equity by 16,701,000.
- Other factors decreased equity by 16,073,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-8.85 Million | -187.29% |
| Share Issuances | €5.07 Million | +107.3% |
| Other Comprehensive Income | €16.70 Million | +353.31% |
| Other Changes | €-16.07 Million | -340.03% |
| Total Change | €- | -40.01% |
Book Value vs Market Value Analysis
This analysis compares Vivoryon Therapeutics NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.14x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.61x to 7.14x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | €2.04 | €1.25 | x |
| 2012-12-31 | €0.73 | €1.25 | x |
| 2013-12-31 | €-0.58 | €1.25 | x |
| 2014-12-31 | €0.00 | €1.25 | x |
| 2015-12-31 | €0.00 | €1.25 | x |
| 2016-12-31 | €0.00 | €1.25 | x |
| 2017-12-31 | €0.00 | €1.25 | x |
| 2018-12-31 | €0.00 | €1.25 | x |
| 2019-12-31 | €3.40 | €1.25 | x |
| 2020-12-31 | €1.31 | €1.25 | x |
| 2021-12-31 | €0.83 | €1.25 | x |
| 2022-12-31 | €1.20 | €1.25 | x |
| 2023-12-31 | €1.04 | €1.25 | x |
| 2024-12-31 | €0.30 | €1.25 | x |
| 2025-12-31 | €0.18 | €1.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vivoryon Therapeutics NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -187.29%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.59x
- Recent ROE (-187.29%) is above the historical average (-64013.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -109.11% | -77652.38% | 0.00x | 1.28x | €-17.80 Million |
| 2012 | -348.93% | -312000.00% | 0.00x | 1.86x | €-19.26 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | €-9.51 Million |
| 2014 | -71611.05% | 0.00% | 0.00x | 1.34x | €-11.44 Million |
| 2015 | -83710.41% | 0.00% | 0.00x | 1.36x | €-13.51 Million |
| 2016 | -84825.35% | 0.00% | 0.00x | 1.37x | €-13.89 Million |
| 2017 | -89756.81% | 0.00% | 0.00x | 1.21x | €-8.01 Million |
| 2018 | -629024.39% | 0.00% | 0.00x | 3.29x | €-7.74 Million |
| 2019 | -18.34% | 0.00% | 0.00x | 1.07x | €-12.09 Million |
| 2020 | -62.96% | 0.00% | 0.00x | 1.13x | €-19.13 Million |
| 2021 | -76.43% | -117.57% | 0.44x | 1.48x | €-14.31 Million |
| 2022 | -106.23% | 0.00% | 0.00x | 1.18x | €-30.81 Million |
| 2023 | -107.84% | 0.00% | -0.12x | 1.17x | €-30.97 Million |
| 2024 | -261.02% | 0.00% | 0.00x | 1.43x | €-21.36 Million |
| 2025 | -187.29% | 0.00% | 0.00x | 1.59x | €-9.33 Million |
Industry Comparison
This section compares Vivoryon Therapeutics NV's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $129,595,294
- Average return on equity (ROE) among peers: -7.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vivoryon Therapeutics NV (VVY) | €4.73 Million | -109.11% | 0.59x | $37.91 Million |
| Galapagos N.V. (GLPG) | $61.14 Million | -10.70% | 0.33x | $1.55 Billion |
| Pharming Group NV (PHARM) | $198.05 Million | -4.93% | 1.15x | $911.43 Million |
About Vivoryon Therapeutics NV
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical tr… Read more